ReviewFrontiers in veterinary science2026
Gut-liver-hypothalamus axis dysfunction in mycotoxin toxicity: mechanisms and protective roles of natural compounds.
Review in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycotoxins, secondary toxic metabolites produced by filamentous fungi, pose significant health risks through contamination of food commodities such as grains. Major mycotoxins, including T-2 toxin, aflatoxins, and ochratoxin, are associated with a range of adverse health effects, particularly gastrointestinal disorders and hepatotoxicity. Increasing attention has been directed toward the gut-liver axis, which plays a critical role in mediating the systemic impact of these toxins, alongside growing interest in natural products as potential therapeutic agents. Natural compounds, including probiotics and antioxidants, have demonstrated the ability to mitigate mycotoxin toxicity through multiple mechanisms, such as toxin binding, inhibition of intestinal absorption, and biotransformation, mediated by pathways including Nrf2-ARE signaling and modulation of antioxidant enzyme activities. This review highlights the complex molecular mechanisms and signaling networks involved in mycotoxin toxicity, with particular emphasis on the gut-liver-hypothalamus axis. Disruption of gut microbiota homeostasis is recognized as a key initial event that compromises intestinal barrier integrity, facilitating toxin translocation to the liver and subsequent effects on hepatic function and hypothalamic hormonal regulation. Emerging evidence supports the potential of natural products as promising therapeutic strategies for restoring the balance of the gut-liver-hypothalamus axis and improving overall health outcomes; however, further research is needed to better elucidate their mechanisms of action and expand their application in the prevention and management of mycotoxin-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.